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http://www.biomedcentral.com/1472-6963/14/284RESEARCH ARTICLE Open AccessExpected lifetime numbers and costs of fractures
in postmenopausal women with and without
osteoporosis in Germany: a discrete event
simulation model
Florian Bleibler1*, Kilian Rapp2, Andrea Jaensch3, Clemens Becker2 and Hans-Helmut König1Abstract
Background: Osteoporotic fractures cause a large health burden and substantial costs. This study estimated the
expected fracture numbers and costs for the remaining lifetime of postmenopausal women in Germany.
Methods: A discrete event simulation (DES) model which tracks changes in fracture risk due to osteoporosis, a
previous fracture or institutionalization in a nursing home was developed. Expected lifetime fracture numbers and
costs per capita were estimated for postmenopausal women (aged 50 and older) at average osteoporosis risk (AOR)
and for those never suffering from osteoporosis. Direct and indirect costs were modeled. Deterministic univariate
and probabilistic sensitivity analyses were conducted.
Results: The expected fracture numbers over the remaining lifetime of a 50 year old woman with AOR for each
fracture type (% attributable to osteoporosis) were: hip 0.282 (57.9%), wrist 0.229 (18.2%), clinical vertebral 0.206
(39.2%), humerus 0.147 (43.5%), pelvis 0.105 (47.5%), and other femur 0.033 (52.1%). Expected discounted fracture
lifetime costs (excess cost attributable to osteoporosis) per 50 year old woman with AOR amounted to €4,479
(€1,995). Most costs were accrued in the hospital €1,743 (€751) and long-term care sectors €1,210 (€620). Univariate
sensitivity analysis resulted in percentage changes between −48.4% (if fracture rates decreased by 2% per year)
and +83.5% (if fracture rates increased by 2% per year) compared to base case excess costs. Costs for women with
osteoporosis were about 3.3 times of those never getting osteoporosis (€7,463 vs. €2,247), and were markedly
increased for women with a previous fracture.
Conclusion: The results of this study indicate that osteoporosis causes a substantial share of fracture costs in
postmenopausal women, which strongly increase with age and previous fractures.
Keywords: Discrete event simulation, Fractures, Health care costs, OsteoporosisBackground
With a lifetime risk of 40% to 50%, an osteoporotic frac-
ture is one of the most likely negative health events in
the remaining lifetime of a 50 year old woman [1]. The
individual probability for a 50 year old woman of experi-
encing an osteoporotic fracture is higher than the prob-
ability of developing an atherosclerotic cardiovascular* Correspondence: f.bleibler@uke.de
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unless otherwise stated.disease (4.1% to 30.7% [2] (depending on risk profile)) or
breast cancer (around 11% [3]).
Studies have shown that a decrease in bone mineral
density (BMD) is a strong predictor for fractures on dif-
ferent sites of the human body [4-6]. According to the
World Health Organization (WHO) a person suffers
from osteoporosis when the person’s BMD is at least 2.5
standard deviations lower (T≤−2.5) than the average
BMD of healthy adults [7]. Clinically, osteoporosis is
characterized ”by low bone mass and microarchitectural
deterioration of bone tissue, leading to enhanced bone
fragility and consequent increase in fracture risk” [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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increase in osteoporosis prevalence rates beyond the age
of 50 occurs in both genders [9,10].
Osteoporotic fractures have serious consequences
on the individual and the societal level. Fracture pa-
tients often have a decreased functional mobility [11],
health related quality of life [12] and are faced with an
increased mortality [13]. Especially for advanced eld-
erly persons, fracture related functional impairment
often necessitates external help from professional
home care services, relatives or friends [11]. In some
cases institutionalization in a nursing home (NH) is
unavoidable [14]. On the societal level fractures have
repeatedly been shown to cause a high economic bur-
den [15-21]. As a consequence of the (expected) demo-
graphic change in Germany [22], the economic burden
due to osteoporotic fractures is likely to increase
strongly in the next decades [17].
Internationally, the economic burden of osteopor-
osis and osteoporotic fractures has frequently been
investigated in the last decade [16,18-21,23]. In con-
trast to the large number of cost studies worldwide,
the evidence for Germany is not abundant. Four of
the available cost studies on osteoporotic fractures
were prevalence based, estimating fracture costs for
a specific year [24-27]. One study used an incidence
based approach to estimate lifetime costs caused by
hip fractures [28]. Another study used a Markov-cohort
model to estimate the cumulative (2010–2050) and yearly
(2010, 2030 and 2050) osteoporosis-attributable costs
of different fracture types [17]. None of these studies
estimated expected numbers and costs for all relevant
fractures occurring over the remaining lifetime. More-
over, expected costs of specific subgroups, e.g. persons
already suffering from osteoporosis, having a prevalent
fracture or living in a NH, were not analyzed.
Our study had different aims. First, a discrete event
simulation model (DES) was developed to estimate the
expected lifetime fracture numbers and costs of six
osteoporotic fracture types for 50 year old women in
Germany. Second, the same estimates for hypothetical
women who never suffer from osteoporosis over their
remaining lifetime were made. Third, lifetime fracture
costs attributable to the risk factor osteoporosis (excess
cost) were calculated which indicate the economic po-
tential of preventing osteoporosis as the main risk fac-
tor for fractures. Finally, lifetime fracture costs were
estimated for women with different risk profiles (with
previous fractures, with osteoporosis, or living in a
NH) and at different starting ages. In summary, our
model should give a deeper insight into the economics
of six osteoporotic fractures in Germany, and should
provide new and valuable information to the international
literature.Methods
Modeling approach
A DES model [29-31] was developed to estimate the ex-
pected lifetime fracture numbers and costs of postmeno-
pausal women (aged 50 years and older) in the German
general population (at average risk getting osteoporosis)
and in those who never suffer from osteoporosis. The
simulation starts in the year 2009 and simulates 50 year
old women until the age of 100 years or death (lifetime
horizon). The included costs are considered from a soci-
etal perspective.
A DES is an individual based simulation technique
where all individuals are simulated one by one [30]. The
main components in DES are entities, attributes, events,
time, resources (optional) and queues (optional) [29]. In
a disease simulation context entities are individuals (e.g.
patients). Individuals have attributes which reflect differ-
ent personal characteristics, for example age, gender,
health status, risk factors or event history. Depending on
the number and combinations of attributes the model
determines the individual’s probability to experience an
event. The individual’s attributes profile is dynamic and
can change at each time point in the model. Changes
can be triggered by time alone (e.g. due to natural aging)
or by events (e.g. occurrence of osteoporosis). Events are
dichotomous (discrete) and can occur simultaneously at
each time point (interval) in the model [29]. Event
initialization is done by comparing a uniform (pseudo)
random number between 0 and 1 with an event prob-
ability or a value of a hazard function. An event occurs
when the random number is smaller (or equal) than the
event probability value [30]. Time can be handled in two
different ways in DES: In an “event driven” simulation
time jumps from event to event, whereas in a “time
driven” simulation time progresses by constant intervals
(e.g. years, months, days) [31]. Optionally, DES can also
handle resource constraints using queuing-systems and
allow for interaction between individuals [29].
In order to estimate the expected lifetime fracture
numbers and costs of a 50 year old woman, we concep-
tualized a “time driven” DES with time intervals of one
year, no resource constraints and no interaction between
individuals. The patient flow diagram in Figure 1 shows
the mechanism of the DES-model: “Circles” represent
start- and end-point of each simulation run (simulation
of one individual n); in “rectangles” events are initialized
whereas “rhombuses” represent decision points which
determine the individual’s way through the model based
on the individual’s attributes. The main events in this
DES are the occurrences of hip, other femur, clinical verte-
bral, humerus, pelvis and wrist fractures. The probability
of a fracture event is influenced by four risk factors (attri-
butes) known from the literature: Age [32,33], osteopor-
osis (BMD) [4-6], prevalent fractures (prev. fx) [34], and
Figure 1 Model process and structure (Flow Chart). Legend of Figure 1: prev. fx = previous fracture, NH = nursing home, av. Inst. = average
NH institutionalization probability, acute fx = acute fracture, fx status = acute or previous fracture, t = time interval, n = individual.
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itself is modeled as an event, e.g. institutionalization in a
NH, and can arise in each time interval. At the beginning
of each simulation run for an individual n the model de-
termines if the individual directly starts with osteoporosis
or a prevalent fracture (preload) [29], based on the age
specific prevalence rates of these risk factors. All women
start with the age of 50 in the base case.
There is evidence that fractures increase the probabil-
ity of institutionalization in a NH [14]. Therefore, the
probability of the event “admission to a NH” (NH entry)
is dependent on acute fracture events (acute fx) and the
age-dependent average institutionalization probability
(av. Inst.). Fractures increase mortality in the year of the
fracture and in the subsequent years [13]; furthermore
it is known that individuals living in a NH have higher
mortality rates compared to those who do not at the
same age [37]. Therefore, whether an individual survives
the actual time interval (“Survival”) depends on age, the
presence of fractures (fx status) in the actual and previ-
ous time interval and the living situation (living in NH
or not). Each individual is simulated until one of the
two endpoint conditions, age of 100 years or death, is
fulfilled. The simulation was programmed in MatlabR2012a (The MathWorks, Inc., Natick, MA, USA) in
combination with Excel 2010 (Microsoft Cooperation,
Redmond, WA, USA).
Cost tracking
Not all fracture patients are treated in an inpatient set-
ting (hospital). Therefore, the model determines on the
basis of fracture specific hospitalization probabilities,
whether a fracture patient is treated in a hospital or ex-
clusively treated in an outpatient setting. If a patient is
treated in a hospital, the model tracks acute hospital
and post-hospital outpatient treatment costs; otherwise
only outpatient costs are tracked. Also, not all patients
receive inpatient rehabilitation after a hospital stay. For
this reason, the same cost tracking approach, based on
fracture specific post-hospital rehabilitation probabilities,
was applied for rehabilitation costs. For tracking fracture-
attributable long term care costs, a parallel background
simulation approach was implemented [20]. The approach
simulates the probability of institutionalization in a NH
for any reason and the fracture specific probability in par-
allel. If a woman is institutionalized due to a fracture, long
term care costs (i.e. yearly NH costs weighted by level of
care as well as capital costs) are tracked as fracture-
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for any other reason [20]. A half-cycle correction was ap-
plied to long term care costs [38].
All other cost categories in the model are tracked as
unit costs (rewards) per fracture event, similar to the
common cohort model approach [38]. A detailed de-
scription of the epidemiological and cost specific input
data used can be found in the electronic supplementary
material (Additional file 1).
Determination of life time costs and fracture events
In total, two risk groups of 200,000 hypothetical women
(simulation runs) each were simulated through the model.
For the first risk group it was assumed that these women
were at average osteoporosis risk over their remaining life-
time (based on osteoporosis incidence and prevalence),
whereas the second risk group was assumed to be free of
osteoporosis over their remaining lifetime. To determine
osteoporosis-attributable fracture costs (excess costs), the
difference in costs between the two considered risk groups
was calculated [17]. To eliminate the stochastic noise be-
tween the two groups (with regard to simulated costs and
fracture numbers), that is the randomly generated differ-
ence between the two groups because of using different
random streams (sequence of random numbers) for each
group, the same random stream (common random num-
bers) was used for both simulated groups [39].
Epidemiological input data
Fracture probabilities – general population
Age-dependent fracture probabilities for all considered
fracture types were calculated based on official German
population [22] and hospital discharge data [40] of the
year 2009. The number of hospitalized fracture cases for
women between 50 and 100 years of age (five-year age
classes) were identified using the international classifi-
cation of disease (ICD-10) with the following codes: hip
S72.0-2, other femur S72.3-9, clinical vertebral S12.0-2/
S12.7/S22.0-1/S32.0, humerus S42.2-4, pelvis S32.1-8Table 1 Total yearly fracture probability of the female genera










95+ 0.03960 0.00382and wrist S52.5-6. Fracture probabilities based on hospital
cases were estimated by dividing the identified fracture
cases from the discharge statistic with the number of per-
sons in the general population in the corresponding five-
year age class (population at risk). While 100% of hip and
other femoral fractures are treated in an inpatient setting
(hospital) [41], some of clinical vertebral, humerus, pelvis
and wrist fractures are treated exclusively in an outpatient
setting [41-44]. Therefore, the estimated fracture probabil-
ities calculated from hospital discharge statistics and
population data underestimate the “total” fracture prob-
abilities, at least for clinical vertebral, humerus, pelvis and
wrist fractures. To include these outpatient fracture cases
in the total fracture probability, the fracture probabilities
estimated based on hospital cases were divided by fracture
specific and age-independent hospitalization probabilities
from the literature (clinical vertebral [41,44,45], humerus
[42], pelvis [43], wrist [42]) (see Additional file 1: A.3.a-b).
The calculated “total” fracture probabilities pertain to
the German female general population (see Table 1).
However, as women were assumed to be in specific living
situations (women with or without osteoporosis, women
with or without a previous fracture, community-dwelling
women or women living in a NH), these general popula-
tion fracture probabilities had to be adjusted.
Fracture probabilities for women with and without a
previous fracture
Clinical studies showed that a previous fracture is an im-
portant risk factor for a subsequent fracture, even after
adjustment for BMD [34]. The age-adjusted risk ratios
for further hip (RRHipPreviousFx vs. NoPreviousFx) and other
osteoporotic fractures (RROsteoPreviousFx vs. NoPreviousFx),
comparing women with a previous fracture to those
without a previous fracture, were taken from a meta-
analysis [34]. However, the risk ratios reported in this
meta-analysis are only applicable to fracture probabilities
of women without a previous fracture. Therefore, in a first
step, age-dependent relative risks for women without al population by age and fracture type
rtebral Humerus Pelvis Wrist
0.00095 0.00085 0.00018 0.00221
0.00144 0.00143 0.00028 0.00390
0.00192 0.00194 0.00038 0.00491
0.00316 0.00272 0.00071 0.00620
0.00456 0.00360 0.00127 0.00684
0.00634 0.00530 0.00285 0.00866
0.01132 0.00716 0.00544 0.00973
0.01378 0.00872 0.00890 0.00916
0.01339 0.00861 0.01172 0.00740
0.01052 0.00795 0.01118 0.00530
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(RRNoPreviousFx vs. GpFx) were estimated. The calculation
method was adopted from Schousboe et al. [46] using the
following formula:
RRNoPreviousFx vs: GpFx ¼ 1=ð1þ RRAnyPreviousFx vs NoPreviousFx‐1
 
PrevPreviousFxÞ
The age-adjusted risk ratios for any fracture compar-
ing women with previous fractures to those without a
previous fracture adjusted for BMD (RRAnyPreviousFx vs.
NoPreviousFx) and age-dependent prevalence rates for pre-
vious fractures (PrevPreviousFx) were both taken from the
previously mentioned meta-analysis [34]. In the second
step the estimated RRNoPreviousFx vs. GpFx were multiplied
with the fracture probabilities of the general population
to obtain fracture probabilities for women without a pre-
vious fracture. If a woman suffered from a fracture in
the model, further fracture probabilities were calculated
by combining fracture probabilities for women without a
previous fracture with RRHipPreviousFx vs. NoPreviousFx and
RROsteoPreviousFx vs. NoPreviousFx depending on the fracture
type (see Additional file 1: A.3.c).
Fracture probabilities for women with and without
osteoporosis
Fracture probabilities for women with osteoporosis were
derived by multiplying the age-dependent female general
fracture probabilities with age and fracture specific relative
risks for women with osteoporosis compared to the female
general population (RROST). The RROST were estimated
based on a method described by Kanis et al. [10]. Ne-
cessary input data such as fracture specific relative risks
by a decrease of one standard deviation in BMD measured
at the femoral neck (RRfx) [4-6], the osteoporosis BMD
threshold [10], and age-dependent population BMD values
(reference values from NHANES III) [47] were taken from
different international studies. To reflect lower fracture
probabilities for women without osteoporosis compared
to the female general population, probabilities were esti-
mated based on a method described by Bleibler et al. [17]
(see Additional file 1: A.3.d-e).
Fracture probabilities for women living and not living in
a NH
There is evidence that women living in a NH have a
higher fracture risk compared to community-dwelling
women [35,36]. To include this in our model, relative
fracture risks for women residing in a NH and for those
who do not, each compared to the female general popu-
lation, were calculated. Basis for the calculation was a
dataset (claims data) from a large German mandatory
sickness fund (Allgemeine Ortskrankenkasse Bayern
(AOK Bavaria)). This dataset contains individual dataabout level of long-term care (e.g. begin of care, admis-
sion to NH), hospital cases by ICD-10 and date of death
for persons aged 65 years and older insured between
January 2004 and June 2009. Relative fracture risks were
determined on pooled cumulative fracture incidence
rates from 2004–2008. Incident hospital fracture cases
by fracture type were identified using the ICD-10 codes
mentioned above. A detailed description of the dataset
can be found in the electronic supplementary material
(see Additional file 1: A.3.f-g).
Probability of developing osteoporosis
The age-dependent probability of developing osteoporosis
was calculated based on osteoporosis prevalence rates
originally estimated from the NHANES III study [9,48].
The osteoporosis prevalence rate was transformed into a
applicable transition probability (incidence) using a method
described by Podgor and Leske [49] (see Additional
file 1: A.2).
Probability of institutionalization in a NH
Especially hip fracture patients in higher age groups
often have persistent reductions in their functional abilities
and mobility after a fracture event [11]. Moreover, they
frequently depend on external care or need to be institu-
tionalized as a result of a fracture [11]. Similar to hip frac-
tures, other types of osteoporotic fractures have been
shown to increase the probability of institutionalization
[14]. To model the association of a fracture event and
institutionalization, crude age and fracture specific prob-
abilities of admission to a NH (within 3 months after
hospitalization) were estimated based on claims data from
the AOK Bavaria. Besides a fracture related transition into
a NH, the model allows institutionalization due to other
reasons. To include this, official long-term care preva-
lence rates from 2009 [50] were transformed into NH
institutionalization probabilities [49]. A transition between
the status community-dwelling and status NH was pos-
sible for women 65 years and older. Similar to other simu-
lation studies, it was assumed that persons in a NH will
remain there for the rest of their lives [51] (see Additional
file 1: A.4.a-b).
Mortality
As main source of mortality, an official generation life
table (all-cause mortality) of women born in 1959 was
used to reflect a realistic remaining life expectancy for a
50 year old woman living in the year 2009 (start year of
the model) [52]. Depending on the actual model state
(community dwelling, NH or fracture), age specific all-
cause mortality was multiplied with state specific rela-
tive risks of mortality. Relative risks of mortality due to
fractures were taken form a Canadian study [13]. The
authors of this study determined the increase in relative
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merus, wrist and other fractures for five age classes and
a follow up period of 10 years separated in 3 categories
(1; 2–5; 6–10 years). They adjusted the calculated rela-
tive risks for co-morbidities and location of residence.
Relative mortality risk for persons living in a NH or in a
community-dwelling setting compared to the female
general population were calculated based on the AOK
Bavaria claims data (see Additional file 1: A.1.a-d).
Cost input data
Fracture related unit costs were estimated from a societal
perspective for Germany. The base year of cost evaluation
was 2009 and a discount rate of 3% was applied [53]. In-
cluded fracture related direct cost were separated in three
main categories: inpatient costs include costs due to acute
hospital care, rehabilitation after hospitalization and long
term care, outpatient costs include costs due to physician
and physiotherapist visits, analgesics (medication) as well
as home care, and family costs include informal care costs.
An overview over the main direct unit costs is shown in
Table 2. Productivity costs were included in the model and
estimated based on the human capital [54] and friction
cost approach [55].
Inpatient costs
In Germany, hospitals are reimbursed according to a
dual system: Operating costs due to direct resource uses
are paid on the basis of a German version of diagnosis
related groups (G-DRG) by health insurance funds (private
or mandatory), whereas capital costs are compensated by
federal states [53]. Therefore, applied hospital costs consist
of fracture related DRGs and capital costs. To determine
the DRG part of total hospital costs per fracture type,
the G-DRG Browser V2010 [56] was used. This dataset
includes information on a large representative sample of
German hospitals in 2009, including number of DRG-
cases, age, gender, disease diagnosis (ICD-10), DRG rela-
tive cost weights and mean length of stay. On the basis of
this information an average relative cost weight and mean
length of stay was calculated for each considered fracture
type and multiplied with a state weighted base rate of
2009 [57] to obtain DRG costs. Capital costs wereTable 2 Overview of direct unit costs in € by cost category an
Cost category* Hip Other
Hospital treatment (plus outpatient aftercare costs) 8,554
Rehabilitation (if required after hospitalization) 2,187
Outpatient costs (if no hospitalization required) n. a.
Professional home care (age > 65, not in NH) 2,174
Informal home care (age > 65, not in NH) 2,361
Yearly long term care cost (age > 65, in NH) 25,759
*A detailed description of all references and calculations can be found in the electrcalculated by combining the fracture specific length of
stay with a daily capital cost rate [58] (inflated to 2009
[59]) (see Additional file 1: B.1.a). Rehabilitation costs
after a hospital stay were estimated by combining the frac-
ture type related duration of an inpatient rehabilitation
treatment [60] with a daily cost rate [61] (see Additional
file 1: B.1.b). Long term care costs are based on the official
care statistic 2009 [50]. This statistic provides information
on daily care costs and number of persons living in long
term care by level of care in 2009. Therefore, level of
care weighted yearly inpatient long term care costs were
calculated. Additionally, capital costs for long term care
[62] were added to the yearly unit costs (see Additional
file 1: B.1.c).
Outpatient costs
Fracture related costs for physician visits (including out-
patient surgeons), physiotherapeutic treatments and an-
algesics for patients exclusively treated in the outpatient
sector, as well as outpatient cost for post-hospital treat-
ment were estimated using German unit costs [58], in-
flated to 2009 [59]. Necessary resource use data in the
three outpatient categories were taken from a German
cost-effectiveness study [63]. The authors of this study
collected information on resource use associated with
hip, vertebral and wrist fractures. It was assumed that
outpatient costs for other femur as well as pelvis frac-
tures are similar to hip fractures and outpatient costs
for humerus fractures are similar to wrist fractures (see
Additional file 1: B.1.d).
Costs for home care per fracture type were determined
based on information about fracture type specific hours
of home care needed [19] and hourly unit costs [64]. As
no information on fracture type specific hours of home
care was available for Germany, a study from Austria
was used [19]. It was assumed that only women older
than 65 years utilize home care. No home care costs
were applied to women living in a NH (see Additional
file 1: B.1.e).
Informal care costs
To reflect the fracture related costs of informal care [65],
fracture type specific amount of hours spend by relativesd fracture type
femur Clinical vertebral Humerus Pelvis Wrist
8,395 6,324 5,764 5,005 3,794
2,187 2,092 2,337 2,177 2,337
n. a. 1,614 835 963 835
2,174 2,212 937 2,174 525
2,361 2,016 2,961 2,361 581
25,759 25,759 25,759 25,759 25,759
onic supplementary material (see Additional file 1: B.1.a-f).
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approach (proxy good) [65]. Each hour of care was monet-
arily valued by the hourly gross salary of an employee in
the field of care for elderly and disabled persons [66], cor-
rected by the employer share of social contribution
[54,67]. As no information about number of hours spend
by relatives of the fracture patients was available for
Germany, Austrian data [19] were used. Similar to home
care costs, it was assumed that women aged 65 or younger
and women living in NH receive no informal care (see
Additional file 1: B.1.f ).
Productivity costs
The model considers two categories of productivity
costs. First, loss in productivity due to the fracture re-
lated inability to perform paid work, and second, the
productivity loss due to osteoporosis related premature
deaths [68]. Productivity loss was evaluated using the
human capital [54] and the friction cost approach [55].
Necessary information, such as employment rate [69],Table 3 Overview of the model assumptions
Assumptions regarding event probabilities
We applied osteoporosis prevalence rates and BMD-values from US-NHANES
We estimated “total” fracture probabilities by dividing fracture probabilities b
probabilities
We assumed highest fracture related NH probability when more than one fra
We modeled fracture related entry in a NH only after a hospital stay
We assumed that only NH entries within 3 months after a fracture may be at
We applied age-dependent relative fracture risk by one standard deviation d
risks to other fractures
We assumed that osteoporosis risk attributions were calculated exclusively on
We assumed that osteoporosis prevalence rates do not differ between wom
We applied relative fracture risk and prevalence for previous fractures from a
We applied relative fracture risk by one standard deviation decrease in BMD
We applied fracture mortality data from a Canadian study
We assumed the highest fracture excess mortality when more than one fract
We allowed first entry in a NH firstly for women aged 65 or older
We assumed that individuals in a NH remain there for their remaining lifetim
We assumed that patients with osteoporosis will have osteoporosis for their
We allowed a maximum possible age of 100 years
Assumptions regarding costing
We assumed that rehabilitation probabilities after a hospital stay do not diffe
We applied Austria data for average hours of informal and professional home
hours are equivalent for hip, other femur and pelvis
We assumed age-dependent fracture unit costs
We assumed that the outpatient costs for humerus and wrist as well as the c
We took outpatient resource use data from a study considering fracture pati
We assumed that average informal and professional home care costs are onl
65 years
§Expected impact on modeling results: * = low impact, ** = medium impact, *** = hiyearly average gross earnings [66] corrected by employer
share of social contribution [67], time away from work
(due to disability and rehabilitation [60]), length of friction
period [70] for the year 2009, were taken from official sta-
tistics. A yearly net wage increase of 2% was assumed
[54,71]. If necessary, a half-cycle correction was applied to
determine costs [38] (see Additional file 1: B.2.a-b).
Model assumptions
In order to improve model transparency, all model as-
sumptions are presented in Table 3, distinguishing between
assumptions regarding event probabilities and costs. Model
assumptions were evaluated subjectively with respect to
their expected impact on modeling results and scored from
1 asterisk (*, low impact) to 3 asterisks (***, high impact).
Scenario analysis
A number of scenarios of direct lifetime fracture costs
were analyzed for women with different start characteris-
tics. Each considered scenario consists of a combination ofImpact§
III reference data ***
ased on hospital cases with age-independent hospital **
ctures occurs in the same time interval **
**
tributable to the fracture event itself **
ecrease in BMD to hip fractures and age-independent relative **
BMD values measured at the femoral neck **
en living in a NH and women who do not *
n international meta-analysis *
from international studies *
*





r between women living in NH and those who do not. **
care by fracture type, also we assumed that the consumed **
*
osts for pelvis, other femur and hip fractures are equivalent *
ents with inflammatory bowel disease *
y applicable for individuals not living in NH aged older than *
gh impact.
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or 75), residential status (community dwelling (C) or NH
(N)), disease status (already suffering from osteoporosis
(O), at average risk of getting osteoporosis (avO) or not at
risk of getting osteoporosis (nO)) and fracture history
(with a previous fracture (P) or with no previous fracture
(nP)). In total we modeled 18 scenarios, and each scenario
was labeled based on the combination of the four start
characteristics e.g. a 50 year old woman, community
dwelling with average risk of getting osteoporosis and
no previous fracture was labeled as 50_C_avO_nP in the
results section. All scenarios were simulated separately,
direct costs are presented undiscounted and discounted
by 3%.
Sensitivity analysis
Deterministic one way and probabilistic sensitivity ana-
lyses were conducted. We performed 20 deterministic
sensitivity analyses (S1-S20) to evaluate the impact on
excess costs due to osteoporosis-attributable fractures:
S1: We valued informal care based on the opportunity
cost approach [65] with an average German 2009 hourly
wage rate (corrected by employer share) [66,67]. S2: We
valued informal care with a minimum hourly wage rate
for employees in the area of health care and nursing intro-
duced in 2010 in Germany [72]. S3: We assumed no ex-
cess mortality due to fractures. S4: We assumed baseline
excess mortality only in the first year but not thereafter.
S5: We assumed 30% of baseline excess mortality only in
the first year, but none thereafter. S6: We did not consider
a previous fracture as a risk factor for further fractures.
S7: We applied the lower relative risk value of the 95%
confidence interval to model the risk factor “previous
fracture”. S8: We applied the upper relative risk value of
the 95% confidence interval to model the risk factor
“previous fracture”. S9: We applied the lower value for
the fracture specific relative risks by a decrease of one
standard deviation in BMD measured at the femoral
neck. S10: We applied the upper value for the fracture
specific relative risks by a decrease of one standard devi-
ation in BMD measured at the femoral neck. S11: We in-
creased the osteoporosis prevalence rate by +30%. S12:
We decreased the osteoporosis prevalence rate by −30%.
S13: We increased all input fracture probabilities by +30%.
S14: We decreased all input fracture probabilities by −30%.
S15: We assumed that only hip fracture patients have an
increased risk to be institutionalized in a NH. S16: We as-
sumed a yearly increase of modeled input fracture inci-
dence rates by +1%. S17: We assumed a yearly decrease of
modeled input fracture incidence rates by −1%. S18: We
assumed a yearly increase of modeled input fracture inci-
dence rates by +2%. S19: We assumed a yearly decrease of
modeled input fracture incidence rates by −2%. S20: We
applied a discount rate of 5%.In order to perform a probabilistic sensitivity analysis,
we simulated 10,000 hypothetical women for each risk
group (simulation runs (n)) 1,500 times (simulations (m))
by varying parameters simultaneously for each of the
1,500 simulations (second-order uncertainty) [73]. Com-
mon distributional assumptions were used for costs, prob-
abilities and relative risks [73] (see Additional file 1: C).
The results of the probabilistic sensitivity analyses are
reported as uncertainty intervals, estimated based on
the percentile method (2.5 and 97.5 percentile) [73].
Results
Base case
Figure 2 shows the expected lifetime numbers of the six
analyzed fracture types of a 50 year old woman for the
two risk groups. Considering a 50 year old woman with
an average risk of getting osteoporosis, there are 0.282
hip fractures expected for her remaining life, whereas
0.119 hip fractures are expected for a woman never suffering
from osteoporosis. Thus, around 57.9% of all expected hip
fractures are attributable to osteoporosis. Wrist fractures are
the second most frequent fracture type, with expected 0.229
fractures for women at average risk of osteoporosis and
0.188 for those not at risk. With around 18.2% of wrist frac-
tures attributable to osteoporosis, this fracture type had the
lowest osteoporosis risk attribution. The lifetime numbers of
other femur, clinical verterbral, humerus and pelvis fractures
for a woman with average osteoporosis risk are expected
at 0.033, 0.206, 0.147 and 0.105 respectively, which cor-
responds to an osteoporosis risk attribution of around
52.1%, 39.2%, 43.5% and 47.5% for these fracture types.
Table 4 displays the expected direct costs for each of the
six fracture types accrued in all considered healthcare sec-
tors, excluding costs due to long term care. In women
with average osteoporosis risk, hip fractures cause €1,277
(39.1%) of all discounted costs. Considering discounted
excess cost due to osteoporosis, hip fractures cause €692
(50.4%) of total excess costs. The fracture types with the
second and third largest contribution to discounted excess
costs are clinical vertebral (15.9%) and humerus (14.9%)
fractures. The lowest share of discounted excess costs was
found for wrist fractures with 4.4%.
Table 5 displays the expected direct lifetime fracture
costs of a 50 year old woman by healthcare sector. Consid-
ering all six fracture types, discounted total costs of a
50 year old woman at average risk getting osteoporosis
amounted to €4,479, of which around €1,995 (44.5%) were
excess costs. With regard to the different healthcare sec-
tors, we found that around 71.3% of the discounted total
excess costs resulted from inpatient treatment, mainly
caused by acute hospital treatments (37.6%) and fracture-
attributable long term care (31.1%). Treatments in the out-
patient sector were responsible for 17.2% and informal
care for 11.5% of these costs.
Figure 2 Expected lifetime numbers of fractures (95%UI) of a 50 year old woman by fracture type and risk class.
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total direct fracture costs per capita for postmenopausal
women by age. It shows that women with average osteo-
porosis risk aged 50–70 years have relatively low annual
costs per capita of €14 to €142, with low osteoporosis
cost attributions of 9.7% to 25.5%. However, a strong in-
crease in these costs and corresponding cost attribu-
tions can be observed beyond the age of 75. The annual
costs per capita increase from €260 for women agedTable 4 Undiscounted and discounted fracture lifetime costs
classes of osteoporosis and excess
Direct cost Undiscounted
By fracture type Average risk
(95%UI)




Hip 3,399 42.7 1,449 34.4 1,95
(2,933-4,116) (398–2,466) (1,070-3,179
Other femur 388 4.9 188 4.5 20
(316–461) (83–270) (106–331
Clinical vertebral 1,452 18.2 880 20.9 57
(1,156-2,042) (504–1,425) (279–983
Humerus 1,182 14.9 664 15.8 51
(951–1,377) (320–846) (299–829
Pelvis 773 9.7 413 9.8 36
(617–958) (173–646) (176–609
Wrist 763 9.6 621 14.7 14
(557–1,070) (423–876) (71–252
Total 7,958 100 4,214 100 3,74
(6,883-8,940) (2,027-6,018) (2,045-5,939
95%UI = 95% uncertainty intervals; costs due to long term care are not included.75 years to around €1,535 for those aged 95, with osteo-
porosis cost attributions of 31.3% to 68.0%. For women
aged 82 and older, excess costs exceed costs for women
never suffering from osteoporosis.
Considering discounted productivity costs due to the
inability to perform paid work, we found only low ex-
cess lifetime costs per capita of around €63 applying the
human capital approach and €22 applying the friction











0 52.1 1,277 39.1 585 30.9 692 50.4
) (1,102-1,541) (204–939) (394–1,108)
0 5.3 157 4.8 85 4.5 72 5.2
) (126–181) (44–114) (39–115)
3 15.3 623 19.1 404 21.3 219 15.9
) (494–886) (251–631) (109–367)
8 13.8 532 16.3 328 17.3 204 14.9
) (422–611) (180–395) (121–318)
0 9.6 295 9.0 169 8.9 126 9.2
) (236–364) (83–253) (63–209)
3 3.8 385 11.8 324 17.1 61 4.4
) (282–550) (229–467) (31–103)
4 100 3,269 100 1,895 100 1,374 100
) (2,814-3,664) (1,064-2,538) (774–2,134)
Table 5 Undiscounted and discounted fracture lifetime costs (€) of a 50 year old woman, by healthcare sector for two
risk classes of osteoporosis and excess
Direct cost Undiscounted Discounted (3%)
By healthcare sector Average risk
(95%UI)












Hospital 4,237 36.2 2,170 36.3 2,067 36.2 1,743 38.9 992 39.9 751 37.6
(3,853-4,500) (1,029-3,085) (1,147-3,322) (1,582-1,830) (565–1,306) (432–1,181)
Rehabilitation 272 2.3 125 2.1 146 2.6 105 2.4 53 2.1 52 2.6
(245–290) (42–182) (87–241) (93–110) (23–72) (31–83)
Long term care 3,731 31.9 1,758 29.4 1,973 34.5 1,210 27.0 590 23.7 620 31.1




1,000 8.6 579 9.7 422 7.4 433 9.7 276 11.1 157 7.9
(418–1,949) (182–1,182) (132–1,017) (182–825) (99–544) (52–370)
Prof. home care 1,105 9.5 605 10.1 500 8.7 443 9.9 257 10.4 186 9.3
(800–1,401) (275–925) (262–843) (320–561) (130–379) (100–308)
Family
Informal care 1,344 11.5 735 12.3 609 10.7 544 12.1 316 12.7 228 11.5
(1,205-1,414) (370–997) (346–991) (487–569) (178–409) (133–365)
Total 11,689 100 5,973 100 5,716 100 4,479 100 2,485 100 1,995 100
(10,406-12,929) (2,533-8,757) (2,988-9,466) (3,942-4,898) (1,258-3,424) (1,076-3,215)
95%UI = 95% uncertainty intervals.
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The scenario analysis in Figure 4 shows that a 50 year
old community-dwelling woman with osteoporosis and
no previous fracture (50_C_O_nP) causes approximately
3.3 fold (€7,463 vs. €2,247) the discounted direct fracturesFigure 3 Annual fracture costs per capita by age for two risk classeslifetime costs of a 50 year old community-dwelling woman
not at risk getting osteoporosis without a previous fracture
(50_C_nO_nP). If a 50 year old community-dwelling
woman with osteoporosis has additionally experienced
a previous fracture (50_C_O_P), the fracture costs areand excess.
Figure 4 Undiscounted and discounted direct fracture lifetime costs (€) of different scenarios (women with different
start characteristics).
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community-dwelling woman never suffering from osteo-
porosis had a previous fracture (50_C_nO_P), discounted
direct lifetime costs are increased by 46% compared to the
same woman with no previous fracture (50_C_nO_nP). In
general, we found that the expected discounted direct life-
time costs of a woman living in a NH are markedly lower
than those of a woman living in a community dwelling set-
ting. This is mainly explained by the high mortality in
women institutionalized in a NH. Moreover, no costs for
facture attributable long term care, professional home care
and informal care were applied to institutionalized women.
Sensitivity analysis
The results of the deterministic sensitivity analyses
are presented in Figure 5, whereas the results of the
probabilistic sensitivity analysis (PSA) can be found in
Tables 4, 5 and Figure 2 reported as 95% uncertainty in-
tervals. Figure 5 shows the percentage difference (−%/+%)
between each univariate sensitivity analysis and the dis-
counted total direct fracture excess costs from the base
case analysis. The largest percentage difference between
costs was found when considering a yearly increase and
decrease of fracture rates by −/+2% (S18/S19) (−48.4%/+
83.5%), varying osteoporosis prevalence by −/+30% (S11/
S12) (−44.1%/+64.4%), and by increasing the discount fac-
tor to 5% (S20) (−47.9%). The sensitivity analysis shows
that neglecting the risk factor “previous fractures” (S6)reduces costs by 26.6%. Assuming that only hip fractures
induce a fracture related institutionalization (S15) de-
creased costs by −13.9%. Applying minimal wage rates to
value informal care (S2) led to a cost decrease of −4.8%,
whereas applying the opportunity cost approach (S1) in-
creased costs by +4.6%. Moreover, assuming no fracture
excess mortality (S3) increased costs by 15.4%, while ig-
noring fracture related mortality effects beyond the year of
fracture occurrence (S4) lead to a cost increase of 1.9%.
Validation
For an internal validation of our model we compared
the modeled fracture incidence rates with the expected
fractures rates (input data) of the female general popula-
tion. We also reported the distribution of the number of
fractures per woman to support internal validity and
transparency of the model estimates. Table 6 shows the
expected and modeled hip fracture rates as well as the
proportion of women with 0 to 6 hip fractures (the same
data for all other fracture types is available in the
electronic supplementary material (see Additional file 1:
D.1.a-b)).
The expected and modeled fracture incidence rates
are very similar (Table 6), which suggests that the pro-
portions of women with different fracture probabilities
(e.g. with and without a previous fracture, with and
without osteoporosis, living in NH or not) are modeled
appropriately.
Figure 5 Deterministic sensitivity analyses, difference (%) between direct fracture excess costs due to osteoporosis from base case
excess costs. Legend of Figure 5: CL = confidence limit; RR = relative risk; SD = standard deviation; BMD = bone mineral density.
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ture incidence rates were compared to epidemiological
studies from Sweden, USA and UK (Figure 6). Addition-
ally, the fracture lifetime risk of a 50 year old woman at
average risk of getting osteoporosis was compared to
other modeling and epidemiological studies. Table 7
shows the (first ever) hip fracture lifetime risk of our
modeling study in comparison with other epidemio-
logical and modeling studies from different countries.
Our estimated (first ever) fracture lifetime risk of 19.8%
for hip fracture is in the range of other simulated lifetime
hip fracture risk estimates. Furthermore, in comparison
with epidemiological studies our estimated hip fracture
lifetime risk and fracture rates (Table 7 and Figure 6) show
a good fit. From a systematic review, comparing world-
wide hip fracture risks, it is known that the hip fracture
risk level in Germany should be between that of Sweden
and USA [74], which is confirmed by our estimates. (The
same data for all other fracture types is available in theTable 6 Modeled and expected hip fracture rates and
proportions of women with 0 to 6 hip fractures
Age Fracture rates Fractures per woman Proportion
expected modeled 0 77.63%
50-54 0.0004 0.0003 1 17.57%
60-64 0.0010 0.0011 2 3.92%
70-74 0.0033 0.0034 3 0.75%
80-84 0.0161 0.0156 4 0.12%
90-95 0.0363 0.0355 5 0.02%
95+ 0.0396 0.0400 6 0.00%electronic supplementary material (see Additional file 1:
D.1.a-b)).
Discussion
Summary and comparison to the literature
The goal of this study was to estimate the expected
lifetime fracture numbers and costs per capita for two
risk groups of German postmenopausal women, that is,
women with average risk getting osteoporosis and women
never suffering from osteoporosis. As key results we found
that discounted lifetime fracture costs of €4,479 can be ex-
pected for a 50 year old woman with average osteoporosis
and previous fracture risk, whereof €1,995 or 44.5% are at-
tributable to the risk factor osteoporosis (excess costs).
For both risk groups, around 70% of costs were due to
inpatient treatment, like acute hospital treatments and
long term care. The fracture type with the largest propor-
tion of direct lifetime costs were hip fractures.
In a previous study [17], we estimated the impact of
demographic change on osteoporosis-attributable frac-
tures costs in Germany from 2010–2050. Since aggregated
costs were calculated, a direct comparison in terms of life-
time costs per capita was not possible. The cost distribu-
tion between fracture types and healthcare sectors are
quite similar in both studies, though. In contrast, in the
present study it was possible to implement the event “NH
entry” directly in the model, which allowed a more precise
estimate of fracture attributable long term care costs.
Internationally, few studies estimated and reported the
average lifetime costs per capita of osteoporotic fractures.
A study from Switzerland [20] found discounted (3%) in-
patient lifetime costs for a person aged 50 (both genders)
of CHF5,400 in the year 2000. In 2009 US$ purchasing
Figure 6 Comparison of modeled hip fracture rates with hip fracture rates from Sweden, UK, and USA.
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whereas we found average lifetime costs of US$PPP5,599
(2009) for a 50 year old woman. The authors of the Swiss
model [20] used a first-order lifetime Markov-model
(individual based simulation) considering three fracture
types (distal forearm, (all) vertebral and hip). They mod-
eled all-cause mortality and excess fracture mortality
for at least 5 years following hip and vertebral fractures.
They considered three fracture related cost categories
from a societal perspective: acute hospital care, in-
patient rehabilitation and hip fracture attributable NH
costs. The difference to our average fracture lifetime
cost may be due to the difference in the number of
modeled fracture types (3 vs. 6) and in included cost
categories. We additionally included costs for fracture
related informal care, professional home care and out-
patient care. Furthermore we assumed that all hospitalized
fractures have an influence on NH institutionalization,
whereas the authors of the Swiss model assumed only hipTable 7 Hip fracture lifetime risk from modeling and
epidemiological studies
Country Study type Hip
Germany* Model – present study 19.8%
Belgium** [75] Model 29.0%
Australia* [76] Model 17.0%
Switzerland [20] Model 20.9%
USA*** [77] Model 24.0%
Sweden* [33] Epidemiological 22.9%
USA* [78] Epidemiological 17.5%
*First ever lifetime risk of a 50 year old woman, **absolute fracture lifetime risk
of 50 year old woman, ***First ever lifetime risk of a 65 year old woman.fractures to have an impact. Additionally we modeled NH
mortality, which may have had a decreasing effect on frac-
ture attributable NH costs. Further differences in average
lifetime costs may be due to different life expectancy, frac-
ture incidence and unit costs assumptions.
A modeling study from Hiligsmann et al. [80] con-
ducted in Belgium found discounted (3%) direct lifetime
fracture costs of €10,288 (US$PPP12,102 (2009)) for
women aged 55 already suffering from osteoporosis,
whereas we found €7,463 (US$PPP9,329 (2009)) for a
woman aged 50 years. The study’s main purpose was to
evaluate the cost-effectiveness of osteoporosis screening
followed by anti-osteoporotic treatment. However, the
authors also reported simulated lifetime fracture costs of
a 55 year old woman with osteoporosis (no intervention
group). The authors used a first-order lifetime Markov
model (Markov-microsimulation). They included hip,
clinical vertebral, forearm and other fractures in their
model. Excess mortality for hip and clinical vertebral
fractures was assumed for the first and subsequent year
[51]. All direct fracture costs from a health-care payer
perspective were included. For hip fractures first year
and long term care costs (due to a NH admission) were
considered. For other fracture types only first year costs
were modeled [51]. The difference in fracture lifetime
cost estimates between our model and the model of
Hiligsmann et al. may have various reasons. We used a
parallel simulation to examine all fracture attributable
NH costs with “real world” NH mortality. Hilligsmann
et al. pre-calculated NH costs due to hip fractures using
average life expectancy assumptions [51]. Also it seems
that Belgian unit costs for hip fracture in the first year
(without NH costs) are higher than our unit costs.
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types (except wrist) and assumed fracture excess mortality
beyond the second year after a fracture, whereas
Hilligsmann et al. considered excess mortality only for hip
and vertebral fractures in the first two years after fracture.
The difference in the cost perspective between the two
modeling studies (health payer perspective vs. societal per-
spective) may also explain the divergence in lifetime costs.
Strengths of the model
In comparison to other models in the field of osteoporotic
fractures, our model has some strengths. Compared to a
Markov cohort model our model allows calculating event
probabilities dependent on the history of a modeled indi-
vidual, which overcomes the classical Markov assumption
of “memorylessness” [38]. Another model type which can
handle patient history is the first-order Markov model
(Monte Carlo simulation) where individuals are simulated
separately through a classical Markov structure (health
states) [38,73]. In comparison to this model type our
model can handle multiple events at the same time
which is not possible in a classical first-order Markov
model because of the mutual exclusivity of health states
[38]. Furthermore, a first-order Markov model would
require a very large number of health states to reflect
the same patient pathways (6 fracture types, previous
fracture (yes/no), osteoporosis (yes/no), NH (yes/no))
that we considered. Applying the event based structure
overcomes this “flood of health states” [30]. From an
epidemiological point of view our model has strengths
in terms of the number of modeled fracture types. In
many models only 3 fracture types (hip, vertebra and
wrist) are considered [81], whereas we modeled 6 fracture
types. In addition, our model allows separating the effect
of osteoporosis, previous fractures, and NH institutiona-
lization on costs. Finally, the model validation showed that
our model reflects the real world epidemiological data very
well and therefore has high validity.
In terms of cost modeling, a main strength of our
model is the large number of cost categories included
and the way how fracture attributable long term costs
are modeled. Using the parallel simulation of NH entries
under real world NH mortality allowed us to estimate
fracture attributable long term care costs more precisely.
Limitations of the model
The results of model-based studies should be interpreted
against the background of the model assumptions, e.g.
model type, time interval, input data. In the model, we
applied age-dependent fracture specific RRfx only to hip
fractures, but not to non-hip fractures. If the age related
patterns of RRfx for hip fractures are similar to other
fracture types, the fracture risk for non-hip fractures in
women with osteoporosis may be overestimated in older,and underestimated in younger age classes. In the model
we applied osteoporosis prevalence rates and BMD data
from a US population (NHANES III study). Applying
these data was necessary, because no German study de-
termined osteoporosis prevalence rates in a comparable
design to the NHANES III study (in terms of osteopor-
osis definition based on BMD (T ≤ −2.5), sample size
and study quality [41]). Furthermore, the prediction of
osteoporosis risk attributions was exclusively based on
BMD values measured at the femoral neck, but not at
other sides, which may have led to an underestimation
of osteoporosis risk attribution on other fracture sites.
Fracture probabilities were mainly estimated based on
the German hospital discharge statistic. In order to in-
clude fracture cases exclusively treated in an outpatient
setting, fracture probabilities from the hospital discharge
statistic were divided by fracture specific hospitalization
probabilities. In our model these hospitalization prob-
abilities were assumed to be age-independent. However,
in a real world setting these probabilities may be age
dependent and increasing with age, which would lead to
an overestimation of total fracture probabilities in younger
and an underestimation in older age classes. Additionally,
we neglected vertebral fractures not coming to clinical at-
tention. However, these fractures likely have a small influ-
ence on costs, but have been shown to increase the risk of
subsequent fractures [82]. In terms of NH probabilities
our model also underlies limitations. We assumed that
only fractures treated in the hospital would increase the
risk of an institutionalization in a NH. However, fractures
treated in the outpatient setting may also increase the
probability of an institutionalization into a NH. Hence, we
may have underestimated fracture attributable long term
care costs as a result. Also, we assumed that only institu-
tionalizations within 3 months were fracture related,
which could have similarly led to an underestimation of
fracture attributable long term care costs.
In terms of cost data, there are further limitations. We
did not consider costs due to transport, medical aids and
early retirement. Cost for osteoporosis specific medication
was also not considered. The main reason for neglecting
medication costs was based on the aim of the study to de-
termine fracture costs attributable to the risk factor osteo-
porosis, and not the cost of treating osteoporosis. A study
which analyzed German insurance claims data found that
the share of osteoporosis medication costs was low in
comparison to other fracture attributable cost categories
[83]. However, this may be due to the low osteoporosis
specific treatment prevalence in Germany [83]. A further
limitation is the assumption that women already residing
in a NH at the time of a fracture event were assumed to
not accrue fracture related long term care costs. In a real-
world setting this assumption may not hold, as fracture
events in a NH can go along with an increase in care
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care costs could not be presented, because all of these
costs were technically attached to a single ”NH” event.
Because of a lack of data we assumed age constant re-
habilitation probabilities after a fracture. However, in a
real world setting these probabilities may differ by age.
Also we assumed that rehabilitation probabilities after a
hospitalization are identical for institutionalized and
community-dwelling women, which may have had an
effect on rehabilitation costs. In reality institutionalized
women may have lower rehabilitation probabilities. As
data on outpatient resource use was only available for
three fracture types (hip, vertebral and wrist), we assumed
the same resource use for fractures in near bone regions
(other femur, pelvis, humerus).
The estimation of expected lifetime fracture numbers
and costs is highly uncertain in terms of changes in age-
adjusted fracture incidence rates (secular trends). Studies
from Europe showed an inconsistent picture of changes
in age-adjusted fracture incidence rates, with increasing
and decreasing trends reported in the last years. Poten-
tial reasons for an increase in age-adjusted hip fracture
rates may be higher survival rates in very old and fragile
persons, a decrease in physical activity and deficiency in
vitamin D [85]. However, there are also potential reasons
for a decrease in age-adjusted fracture rates, which may
be due to improved medical treatment of osteoporosis
(e.g. introduction of bisphosphonates), changes in habits
related to fracture increasing risk factors (e.g. smoking
or heavy drinking) or due to higher prevalence rates in
obesity in the past years [85]. Considering the current
situation of treating osteoporosis in Germany, it seems
that there is room for improvements in terms of detect-
ing and treating osteoporosis. Currently only around
18% of osteoporosis patients receive an osteoporosis
specific treatment [83]. Furthermore, only 14% of frac-
ture patients receive an osteodensitometry, which may
indicate an under-detection of osteoporosis [83]. More-
over, the adherence to oral osteoporosis medications is
suboptimal [86]. Improving detection and medical treat-
ment of osteoporosis in the future could lead to a decreas-
ing secular trend in fracture incidence rates in the future
in Germany, which should also lead to a decrease in ex-
pected fracture lifetime numbers and costs. On the other
hand, the predicted demographic change in Germany [22]
may have an increasing effect on future age-adjusted inci-
dence rates and therefore may increase lifetime fracture
numbers and costs.
Implications for decision makers
The results of this study show that fractures cause relevant
costs in postmenopausal women, which strongly increase
with age, previous fractures and osteoporosis status. The
high costs in age classes over 70, in combination withdemographic change, could in addition intensify the eco-
nomic burden due to fractures in Germany [17]. Thus,
tackling fractures in a cost-saving or cost-effective way
should be an important goal for German health care
decision makers.
In the future, our model can be used to perform cost-
effectiveness analyses of fracture prevention interven-
tions in Germany. Beside the described model func-
tions, we optionally implemented an osteodensitometry
module. This feature makes the modeling of different
screening to treat scenarios for Germany possible. More-
over, the real-world adherence of medical anti-osteoporotic
therapy can be realistically implemented in the model.
As prior studies found cost-effectiveness results to be
highly sensitive to medication adherence assumptions, a
realistic implementation of the respective empirical evi-
dence seems particularly important in health economic
modeling of osteoporotic fractures [87].Conclusion
This is the first analysis modeling the epidemiology and
costs of fractures for Germany. The analysis shows that
44.5% of all discounted direct fracture lifetime costs of a
50 year old woman are attributable to osteoporosis. For
a 50 year old woman already suffering from osteoporosis,
fracture lifetime costs are expected to be 3.3 fold the frac-
ture costs of a healthy woman at the same age. The main
cost drivers are hospital and long term care costs, causing
around 70% of total fracture related lifetime costs. Beyond
cost of illness, the model can be used to evaluate the cost-
effectiveness of fracture prevention.Additional file
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